The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Mel'nichenko O.O.

V.G. Korolenko City Clinical Hospital №14, Health Department of the city of Moscow

The use of tacrolimus for the treatment of atopic dermatitis

Authors:

Korsunskaia I.M., Nevozinskaia Z.A., Mel'nichenko O.O.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2011;9(5): 86‑91

Read: 4285 times

Download PDF (RU)
Contact the author
Table of contents

THE USE OF TACROLIMUS FOR THE TREATMENT OF ATOPIC DERMATITIS
THE USE OF TACROLIMUS FOR THE TREATMENT OF ATOPIC DERMATITIS

To cite this article:

Korsunskaia IM, Nevozinskaia ZA, Mel'nichenko OO. The use of tacrolimus for the treatment of atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology. 2011;9(5):86‑91. (In Russ.)

 
Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Xero­sis as the basis of dermatoses in an elde­rly age. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):592-596
Dyna­mics of Substance P and Fila­ggrin Levels on Combined Treatment of Atopic Dermatitis with Emollient and Topi­cal Anti­pruritic Drug in Pregnant Women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):662-666
Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspe­cts and patient mana­gement tactics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):744-752
Infe­ctious factors in atopic dermatitis, pharmaceutical possibilities (systematic lite­rature review). Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):7-15
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Asse­ssment of the serum inte­rleukin 33 (IL-33) level in patients with atopic dermatitis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):293-296
Gene­sis of emollients. Past, present, future. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):412-420
From atopy to infe­ction — a clinical case of combined skin pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):430-436
Mechanisms of addi­tivity of physiotherapeutic factors in complex therapy of poly­pous rhinosinusitis complicated by como­rbidities. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):5-11
Abstract:

Keywords:

topical inhibitors of calcineurine
tacrolimus
atopic dermatitis

Authors:

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Mel'nichenko O.O.

V.G. Korolenko City Clinical Hospital №14, Health Department of the city of Moscow

Close metadata

References:

  1. Williams H., Robertson C., Stewart A. et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103: 125-138.
  2. Laughter D., Istvan J.A., Tofte S.J., Hanifin J.M. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000; 43: 649-655.
  3. Boguniewicz M., Leung D.Y.M. New concepts in atopic dermatitis. Comp Ther 1996; 22: 144-151.
  4. Chapman M.S., Schachner L.A., Breneman D. et al. Tacrolimus ointment 0-03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 2005; 53: S177-S185.
  5. Korting H.C., Unholzer A., Schafer-Korting M. et al. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002; 15: 85-91.
  6. Brazzini B., Pimpinelli N. New and established topical corticoster-oids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58.
  7. Instruktsiya po meditsinskomu primeneniyu preparata Protopik. LSR-001885/10-120310.
  8. Reitamo S., Wollenberg A., Schopf E. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006.
  9. Paller A.S., Lebwohl M., Fleischer A.B. et al. Tacrolimus Ointment is more effective than Pimecrolimus cream with a similar safety profile in the treatment of Atopic Dermatitis: Results from 3 randomized. Comparative Studies. JAAD 2005; 52: 5: 810-822.
  10. Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-555.
  11. Reitamo S., Van Leent E.J., Ho V. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-546.
  12. Wahn U., Bos J.D., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatiris in children. Pediatrics 2002; 110: e2.
  13. Kapp A., Papp K., Bingham A. et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-284.
  14. Doss N., Reitamo S., Dubertret L. et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol 2009; 161: 427-434.
  15. Carroll C.L., Fleischer A.B. Tacrolimus: Focusing on atopic dermatitis. Drugs Today 2006; 42: 7: 431-439.
  16. Remitz A., Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf 2009; 8: 4: 501-506.
  17. Ingram J.R., Martin J.A., Finlay AY. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2009; 10: 4: 229-237.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.